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Time flies when you are having fun.... And even more so when you are not. Faced with the evolving COVID‐19 pandemic, it is easy to forget last year\'s very relevant epidemic of e‐cigarette, or vaping, product use‐associated lung injury (EVALI). EVALI risk within the vaping public represents a substantial escalation of preventable co‐morbid risk that can dramatically and negatively impact the pulmonary inflammatory morbidity and mortality of COVID‐19 if social behaviors are not effectively and dramatically curbed through effective public health measures. Within this epidemic/pandemic cycle, it is especially alarming that the footprint of the EVALI epidemic nearly mirrors that of current COVID‐19 pandemic reported cases, thus matching regional social behavior risk with current regional pandemic risk[1](#lio2386-bib-0001){ref-type="ref"}, [2](#lio2386-bib-0002){ref-type="ref"} (Figure [1](#lio2386-fig-0001){ref-type="fig"}).
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As a brief epidemic review, from April 2019 through February 2020, 2807 EVALI hospitalizations and 68 deaths were reported within the U.S. adolescent and millennial populations.[^1^](#lio2386-bib-0001){ref-type="ref"} Eighty‐two percent of patients reported using tetrahydrocannabinol (THC)‐containing products and 57% using nicotine‐containing products. Of those who reported using THC‐containing products, 16% obtained them from regulated commercial sources (recreational and/or medical dispensaries, vape or smoke shops, and stores), 78% from nonregulated/quality controlled sources (family/friends, street transactions, online sources), and 6% from both commercial and nonregulated/quality controlled sources. Vaping associate pulmonary injury (VAPI) and EVALI disease severity were reflected in the reported duration of hospitalization and intubation rates by age group: (a) 13 to 17 years old (8 days/30%); (b) 18 to 24 years old (6 days/15%); (c) 25 to 50 years old (7 days/20%); and (d) \>50 years old (15 days/52%).[^3^](#lio2386-bib-0003){ref-type="ref"}

Looking at the big picture for potential VAPI/EVALI comorbid risk escalation within the COVID‐19 pandemic, in 2019 the reported incidence of vaping or electronic nicotine delivery system (ENDS) use in the United States was as follows: 10.5% of middle school students, 27.5% of high school students, 21% of millennials (age 23‐28), and 18% of generation X (age 39‐54).[4](#lio2386-bib-0004){ref-type="ref"}, [5](#lio2386-bib-0005){ref-type="ref"} Recent COVID‐19 societal/social disruption within this population resulting from loss of school and work social structure, as well as stress related home confinement parent/child interactions, are likely not conducive to a reduction in previously reported vaping activity and likely represent a correlated risk of an increase in utilization.

Within public health prism, pulmonary inflammation resulting from vaping/ENDS use within the adolescent and millennial populations significantly raises the COVID‐19 pulmonary morbidity within what should be the healthiest COVID‐19 risk groups. Frank discussion with at risk patients will be an important preventative care strategy within the environment of the rising pandemic risk.

When considering cessation strategies, it is very important to understand the addictive nature of vaping/ENDS delivery systems. A single JUUL e‐cigarette pod, the most popular ENDS on the market, contains as much nicotine as a pack of 20 cigarettes.[^6^](#lio2386-bib-0006){ref-type="ref"} Daily JUUL users report using about 10 pods per month through 4 to 9 daily vaping sessions.[^7^](#lio2386-bib-0007){ref-type="ref"} FDA approved transdermal nicotine dosing systems for smoking cessation are available in 7, 14, and 21 mg/day in over‐the‐counter packaging and may be necessary to combat nicotine withdrawal in heavy vaping/ENDS users attempting to quit.

Otolaryngologists and primary care physicians are on the ambulatory front line of the COVID‐19 identification and isolation pathway for patients given the early onset of sino‐nasal unified airway symptoms and can play a significant public health role in educating the public on the risks of vaping/ENDS use during this current pandemic.
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